Akari Therapeutics Expands Global IP Portfolio with Australian Patent for RNA Splicing ADC Payload
Event summary
- Akari Therapeutics secured Australian patent approval for its proprietary PH1 RNA splicing modulator ADC payload, covering composition-of-matter claims for Thailanstatin analogs.
- The patent strengthens Akari’s global intellectual property portfolio, which now includes issued patents in the U.S., China, India, Japan, Israel, and Mexico.
- Akari’s lead program, AKTX-101 (TROP2-targeting ADC), is in IND-enabling studies with a Phase 1 trial expected in late 2026/early 2027.
- The TROP2-targeted therapies market is projected to reach ~$12B by 2033, according to DataIntelo.
The big picture
Akari Therapeutics’ Australian patent approval further solidifies its global IP strategy, critical for defending its novel RNA splicing modulator payload in the competitive ADC market. The patent strengthens Akari’s position as it advances its lead candidate, AKTX-101, into clinical trials, targeting a rapidly growing TROP2 ADC market projected to reach $12B by 2033. This move underscores the importance of intellectual property in the biotech sector, where differentiation through novel payloads can drive market disruption.
What we're watching
- IP Strategy
- Whether Akari can sustain its global IP expansion to maintain a competitive edge in the ADC space.
- Clinical Execution
- The pace at which AKTX-101 advances through IND-enabling studies and into Phase 1 trials.
- Market Dynamics
- How the $12B TROP2-targeted therapies market evolves and whether Akari can capture significant share.
Related topics